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Natural killer1. Introduction
Adoptive transfer of antigen receptor-redirected T cells has shown
great therapeutic potential in cancer treatment and achieved remark-
able remissions in advanced cancers [1,2]. Due to the risk of rejection
of allogeneic cells, current adoptive cell therapy approaches mostly
rely on the administration of engineered autologous T cells [3,4].
Reaching signiﬁcant numbers of therapeutic redirected patient T cells
is challenging both in terms of logistics and costs independently of theerapy, Oslo University Hospital
g), sebastw@rr-research.no
. This is an open access article underimprovements of ex vivo activation and expansion protocols [5]. To
overcome these manufacturing challenges, the applicability of unre-
stricted sources of antitumor effector cells has been explored and is cur-
rently receiving increasing attention [6–8]. Indeed, cell lines represent a
continuous and unlimited source of effector cells. The FDA approved
Natural Killer (NK)-92 cell line represents a model of universal cells: it
was isolated from a lymphoma patient, established [9] and has been
used in the clinic for at least two decades [7,10]. Earlier data from
phase I clinical trials have shown safety of infusing irradiated NK-92
cells into patients with advanced cancer [11,12].
AlthoughNKcells have an inherent capacity to recognize cancer cells
regulated by a balance between activating and inhibitory signals, they
have limited targeting competence. NK-92 were genetically improved
to express receptors such as Chimeric Antigen Receptors (CARs)
[13,14] or CD16 [15,16]. In both cases the technology relied onthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Redirection of NK cells for clinical use in cancer therapy has been
suggested for almost 20 years. Indeed non-modified NK cells
were not as potent as T cells in detecting targets and mounting
an immune response. The use of artificial receptors such as Chi-
meric Antigen Receptors (CARs) is now tested in the clinic and
demonstrates that with improved targeting, NK cells can become
attractive for such treatment.
Added value of this study
TCR, a natural antigen receptor, can potentially recognize any pro-
tein and therefore represents a receptor which could redirect cells
against any tumor. Although T- and NK cells seem to originate
from the same ancestor cell, alpha/beta T-cell receptor expression
seems to be truly restricted to T cells. This is probably due to the
lack of a complete set of CD3 subunits in NK cells. We here
show that the “simple” addition of the CD3 complex can turn the
NK cell line into a T cell. In addition, this makes it possible to redi-
rect NK cells against any target.
Implication of all the available evidence
Our results not only complete the previous studies enhancing
NK-92 (andNK cells) but also provide evidence about thedistance
between T- and NK-cell lineages. These data will most probably
pave the way to the development of less expensive TCR-based
cell therapy.
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Speciﬁc target antigens represent a bottleneck in CAR-based adoptive
transfer, especially for solid tumors treatment. Unlike antibodies
which directly bind to their targets, T-cell Receptors (TCRs) recognize
an antigenic peptide from degraded protein presented in the context
of a Major Histocompatibility Complex (MHC) molecule. Thus TCRs
can potentially recognize the proteome without restriction to subcellu-
lar localization.
We here asked if a therapeutic NK cell line could accommodate TCR
expression, keeping in mind that a TCR molecule requires a battery of
signaling components to be correctly expressed at the plasma mem-
brane and to signal upon peptide-MHC (pMHC) binding [17]. We par-
tially reconstituted a TCR friendly environment by expressing the CD3
complex, which is necessary for proper TCR targeting to the plasma
membrane and selected a derivative of NK-92 named TCR-NK-92.
Gene expression analysis demonstrated that TCR-NK-92 had acquired
a T cell-like proﬁle. We further observed that TCR-NK-92, unlike the
original NK-92, could express TCRs and that these TCRs were functional
and could trigger pMHC-speciﬁc cytotoxic functions. Considering the
limitless propagation of these cells, the potential TCR-recognition of all
cellular proteins and the possibility of creating TCR-NK-92 biobanks,
we propose the use of these cells for TCR-based cancer immunotherapy.2. Materials and methods
2.1. Ethical statement
All procedures performed in studies involving humanmaterial were
in accordance with the ethical standards of the institutional and the re-
gional ethical committee (REC). Healthy donor T cells were obtained
from buffy coats from the Blood bank under informed consent.Animal experimentswere performed in accordancewith the institu-
tion rules and Norwegian Food Safety Authority approval, mice were
bred and kept in-house under approved animal care protocols.
2.2. Cell lines, media and peptides
T cells were isolated from the blood of healthy donors. NK-92 cells
(human natural killer cell line) were obtained from ATCC and main-
tained in X-vivo 10 (Lonza, Basel, Switzerland) supplemented with 5%
heat-inactivated human serum (Trina Bioreactives AG, Nänikon,
Switzerland) and 500 IU/mL rhIL-2 (Novartis, Emeryville, CA, USA).
K562 cells (erythroleukemia, chronic myelogenous leukemia (CML))
were obtained from ATCC. K562:HLA-A2 and K562:HLA-A2-GFP were
created through retroviral transfection of an HLA-A2 (Addgene
#108214) or an HLA-A2-GFP (Addgene plasmid #85162) construct
[18] and sorted to purity. Jurkat 76 (J76) were kind gifts from M.
Heemskerk (Leiden University Medical Center, The Nederland), Jurkats
(J6) and HCT116 (epithelial colon colorectal carcinoma) were from
ATCC; Granta-519 (mantle B cell lymphoma) were from our collection
and ESTAB039 (melanoma cells) were kindly provided by Graham
Pawelec (University of Tuebingen, Germany). All cell lines were main-
tained in RPMI-1640 (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
supplementedwith 10% FCS (HyClone, Logan, UT, USA) and gentamycin
0.05 mg/mL (Thermo Fisher Scientiﬁc). Target cells used in the BLI
killing assay, in vivo experiments or in microspheroid assays were
transducedwith a retrovirus encoding a luciferase-GFP fusion transgene
[19]. They were sorted for GFP positivity and maintained as a pure line.
The TGFβRII frameshift peptide131–139(RLSSCVPVA) and
peptide127–145 (KSLVRLSSCVPVALMSAMT) and the Melan-A
peptide26–35(EAAGIGILTV)weremanufactured by ProImmune Ltd. (Ox-
ford, UK). Melan-A:HLA-A2 dextramer was from Immudex (Copenha-
gen, Denmark).
2.3. DNA constructs, retroviral transduction, generation of TCR-NK-92 cells
The human polycistronic CD3 complex (hCD3) was designed as de-
scribed in [20], brieﬂy the human coding sequence of the four different
components of the CD3 signaling complex CD3ζ, CD3ε, CD3δ, CD3γ
(UniProt: P20963, P07766, P04234 and P09693, respectively) were
fused via picornavirus 2A coding sequences as depicted in Supplemen-
tary Fig.1. A codon optimized synthetic DNA fragment was ordered
(Euroﬁns, Germany) and subcloned into pMP71 retroviral vector using
our Gateway compatible strategy [21].
TCR expression constructs, Radium-1 and DMF-5, were prepared as
previously described [21,22].
The Luciferase-GFP construct was a kind gift R. Löw (Eufets,
Germany) [23], the coding sequence was veriﬁed and subcloned into
pMP71.
Viral particles were produced as described in [21] and used to trans-
duce cells, either NK-92 (hCD3_2A and TCR) or cell lines (Luciferase-
GFP, HLA-A2). Spinoculationwas performedwith 1 Volume of retroviral
supernatant in a 12-well or a 24-well culture non-treated plate (Nunc
A/S, Roskilde, Denmark) pre-coated with 50 μg/mL retronectin (Takara
Bio. Inc., Shiga, Japan). NK-92 cells were spinoculated twice whereas
other cell lines only once. Cells were then harvested and grown in
their medium. Transduction efﬁciency was checked after 3 to 7 days
by ﬂow cytometry and cells were expanded for future experiments.
TCR-NK-92 cells were generated in two-steps; ﬁrst, NK-92 were
changed to CD3-NK-92 by transduction with hCD3_2A construct and
efﬁciency was monitored by electroporation with an mRNA encoding
for a TCR which triggers a transient CD3 expression at the surface. The
CD3-NK-92 cell line was sorted on the basis of CD3 expression, ampli-
ﬁed and stocked for further use. For TCR expression, CD3-NK-92 were
spinoculated twice with retroviral particles encoding for selected TCR
and sorted for stable CD3 expression. Pure cells were ampliﬁed and
stocked until further use.
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Total RNA was isolated from three biological replicates for each cell
line, NK-92, CD3-NK-92 and TCR-NK-92, using miRNeasy Mini Kit
(Qiagen©) and the RNA integrity was investigated with the 2100
Bioanalyzer (Agilent Technologies Inc., CA, USA). Sequencing libraries
were generated using TruSeq stranded mRNA kit (Illumina Inc., CA,
USA) and 500 ng high quality total RNA (RIN N 8.0) was processed
according to manufacturer's instructions. The resulting libraries were
sequenced 75 bp single read on the NextSeq500 system (chemistry
v2; Illumina Inc., CA, USA).
For differential gene expression analysis sequencing data were ﬁrst
aligned against human reference (UCSC hg19) using STAR v2.5.0 and
expression levels and differential gene expression were assessed with
cufﬂinks/cuffdiff v2.2.1. Further, Ingenuity Pathway Analysis tool
(IPA®, Qiagen©) was used to investigate possible biological down-
stream effects of differential expressed genes.
2.5. TCR-ligand dissociation kinetic measurements by 2-color NTAmers
technology
NTAmers were synthetized and used as described [24]. Shortly, TCR-
NK-92 or T cells were incubated for 40 min at 4 °C with reversible
Melan-A:HLA-A2 speciﬁc NTAmers made of streptavidin-PE scaffolds
and Cy5-labeled monomers. After washing, 0.25 millions cells were
suspended in 250 mL 4 °C FACS buffer and baseline geometric mean
ﬂuorescencewasmeasured on a SORP-LSR II ﬂow cytometer (BD Biosci-
ences, San Jose, CA, USA) for 30 s with constant temperature control at
4 °C. After baseline measurement, imidazole (100mmol/L ﬁnal concen-
tration) was added to elicit the decay of the NTAmer scaffold, enabling
direct visualization of the Cy5-pMHC monomeric dissociation from the
TCR through time. Flow-cytometric-based data were processed using
the kinetic module of FlowJo software v.9.6 (TreeStar Inc., Ahsland,
OR, USA) as described in ref. 16. Normalized (Cy5) gMFI values for
each cell types were plotted against time (s) using the GraphPad
Prism v.6 software (GraphPad Software, San Diego, CA, USA). Mono-
meric dissociation rates best ﬁtted a one-phase exponential decay equa-
tion, from which koff and half-lives could be determined.
2.6. Metabolic analysis
A Seahorse Extracellular Flux (XF96e) Analyzer (Agilent, Santa Clara,
CA, USA) was used to measure the oxygen consumption rate (OCR)
which relates to mitochondrial respiration and the extracellular acidiﬁ-
cation rate (ECAR) that reﬂects the cellular glycolytic activity of live
lymphocytes cells. Brieﬂy, prior to the assay, NK-92, CD3-NK-92, TCR-
NK-92, J6, J76 and J Radium-1 cells were attached onto Cell-Tak
(Corning Inc., Corning, NY, US), with or without anti-CD3 (OKT3)
(eBiosciences, Thermo Fisher Scientiﬁc), coated 96-well XF-PS plates
(Agilent, CA, USA) at a density of 1 × 105 cells/well in DMEM
(ThermoFisher Scientiﬁc) XF unbuffered assay media, supplemented
with 2 mM sodium pyruvate (Sigma-Aldrich, Norway), 10 mM glucose
(Sigma-Aldrich), 2mM L-glutamine (Thermo Fisher Scientiﬁc), adjusted
to physiological pH (7.6) and incubated in the absence of CO2 for one
hour prior to seahorsemeasurements (7 replicates per experiment). Ini-
tially, the cell basal respiration was measured for all groups. Next,
oligomycin (Sigma-Aldrich), a potent F1F0 ATPase inhibitor (1 μM),
was added and the resulting OCR was used to derive ATP production
by respiration (by subtracting the oligomycin-linked OCR rate
from the baseline cellular OCR). Then, 1 μM of carbonyl cyanide
p-triﬂuoromethoxyphenylhydrazon (FCCP) (Sigma-Aldrich) was
injected to uncouple the mitochondrial electron transport from ATP
synthesis, thus allowing the electron transport chain (ECT) to function
at its maximal rate. The maximal respiration capacity was derived
from each group by subtracting non-mitochondrial respiration from
the FCCP measurement. Lastly, a mixture of antimycin A (Sigma-Aldrich) and rotenone (Sigma-Aldrich) was added, at 1 μM, to
completely inhibit the electron transport and hence respiration, reveal-
ing the non-mitochondrial respiration. The basal glycolytic rates were
also measured as ECAR before and after injection of oligomycin
(Sigma-Aldrich). Upon addition of oligomycin the cells switched to
their highest glycolytic capacity to compensate for ATP requirements.
2.7. Reﬂection interference contrast microscopy (RICM) and total interfer-
ence reﬂection ﬂuorescence (TIRF)
Anti HLA class I and CD3 (OKT3) antibodies (eBiosciences) were
adsorbed directly on glass slides, previously washedwith piranha acidic
solution (70% of 96% pure sulphuric acid (Sigma Aldrich) with 30% of
25% pure hydrogen peroxide (Sigma Aldrich)), for 30 min at room
temperature, then washed extensively with miliQ water. TCR(Radium-
1)-NK-92, CD3-NK-92, NK-92 and T cells from PBMC were washed
twice and resuspended at 0.6 × 106 cells/mL in PBS 0.1% BSA and incu-
bated on the glass slides for 20 min under controlled atmosphere
(37 °C and 5% CO2). To trigger the formation of immune synapse, prior
to incubation on coated glass slides, cells were marked with 2 μg/mL
of FITC Anti Vβ3 during 15 min. Cells were then ﬁxed using 4% PFA so-
lution (Sigma Aldrich) for 15 min and then permeabilized in 0.05% Tri-
ton X-100 solution (Sigma-Aldrich) for 15 min. Actin and CD3
molecules were stainedwith 5 μMof Alexa488 Phalloidin (Life Technol-
ogies, Norway) and 2 μM of Atto647 conjugated anti-CD3 antibody
(home-made conjugation, clone UCHT1), respectively, for 30 min.
Cells were imaged using Total Internal Reﬂection Microscopy (TIRFM)
and Reﬂection Interference Contrast Microscopy (RICM) using an
inverted microscope (AxioObserver, Zeiss, Göttingen, Germany),
equipped with an EM-CCD camera (iXon, Andor, Belfast, North-
Ireland). Immune synapse was imaged on a Zeiss 880 LSM microscope
using a GaAsP PMT. Acquisitions were performed using ZEN blue or
black software. TIRF and RICM images were taken with a custom 100
× 1.46 NA oil apochromatantiﬂex objective (Zeiss) or a 63× axioplan
1.4 NA oil objective (for the LSM). Analysis was performed using
home-made programs in Fiji software software as described in [25].
Brieﬂy, in RICM, the region of the cell that resides in the vicinity of the
substrate and in particular its contour, exhibits a high spatial intensity
variance that permits an easy segmentation from the background,
which exhibits low variance, permitting thus to calculate the spreading
area. Actin centrality was measured as the ratio of the ﬂuorescence in a
central disk of 1/5 the cell radius divided by the totalﬂuorescence under
the cell.
2.8. CyTOF
Sixmillion effector cells (T cell, NK-92, TCR(Radium-1)-NK-92)were
incubated with Granta-519 cells, loadedwith TGFβRII peptide127–145, at
1:2 effector: target ratio for 24 h prior CyTOF experiment. Brieﬂy, cells
were resuspended in Maxpar Cell Staining buffer (Fluidigm, san
Francisco, CA, USA) in the presence of 1× cisplatin (Fluidigm) and incu-
bated for 5 min at RT. Cells were washed with PBS and incubated with
Fc-receptor blocking solution (aggregation of G-globulin) for 10 min
and then incubated with the antibody mix, CCR6, CCR7, CD127,
CD137, CD14, CD161, CD16, CD19, CD25, CD279 (PD1), CD28, CD3,
CD33, CD38, CD4, CD45RA, CD45RO, CD56, CD8, CTLA-4, CXCR3,
CXCR4, CXCR5, HLA-DR, ICOS, LAG3, NKG2D, PD-L1, PD-L2, TIGIT,
TIM3 (Fluidigm) for 30 min at RT. Samples were washed twice with
PBS, ﬁxed with 4% of PFA and permeabilized with methanol for 1 h.
After two washes in PBS, cells were resuspended in PBS containing 1×
intercalator (Ir) (Fluidigm) and incubated for 20 min at RT. Following
one wash in PBS cells were pelleted until ready to run in CytOF. Prior
to sample acquisition cells were resuspended in water with 10% of cal-
ibration beads and ﬁltered before being injected into the CyTOF 2 ma-
chine (Fluidigm). Analysis was performed using CytobankCytomass
(http:// www.Cytobank.org). Typical gating strategy was applied as
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length vs Ir-191 to gate singlets. 3. Cisplatin vs CD458-89Y to gate live
cells.4. Event length vs CD19 to exclude CD19+ cells (Granta-519).
Gated events were then run using viSNE algorithm with the following
parameters: 1000 iterations, 30 perplexity, 0.5 theta.
2.9. In vitro cytokine release
TCR-NK-92 and CD3-NK-92 were co-cultured for 24 h with antigen
presenting cells (APCs) loaded with either the cognate peptide or an ir-
relevant peptide, at an effector cell to target cell ratio of 1:2. Culture su-
pernatant was harvested and the cytokine release was measured using
the BioplexPro™ Human Cytokine 17-plex Assay (Bio-Rad Laboratories
Inc., Hercules, CA, US) according to manufacturer's instructions. The
analysis was performed on the Bio-Plex 200 system instrument from
Bio-Rad Laboratories.
2.10. In vitro degranulation assay and phenotype by ﬂow cytometry based
technology
TCR-NK-92 cells were stimulated for 5 h with antigen presenting
cells (APCs), loaded or notwith the indicatedpeptide at 10 μMﬁnal con-
centration, at an effector cell to target cell ratio of 1:2, in the presence of
BD GolgiPlug and BD Golgistop (BD Biosciences) at a 1/1000 dilution.
Cells were then washed extensively and surface stained for ﬂow cyto-
metric analysis (see below) using speciﬁc antibodies. Antibodies spe-
ciﬁc for CD3 (OKT-3), CD56 (TULY56), CD16 (eBioCB16), NKp30
(AF29-4D12), NKp44 (44.189), NKp46 (9E2), NKG2D (1D11), CD226
(DX11), CD137 (4-B41), CD96 (TACTILE) (NK92.39), CD94 (DX22) and
TIGIT VSTM3 (A15153G) were used to proﬁle the effector receptors.
Anti CD107a (H4A3) antibody was used as measurement of degranula-
tion functions. Anti Vβ3 (CH92) antibody (Beckman Coulter) was used
to monitor the expression of the therapeutic TCR (Radium-1) and
Melan-A:HLA-A2 dextramer (Immudex) for monitoring DMF-5 TCR.
For surface staining single-cell suspensions were stained with the ap-
propriatemonoclonal antibodies for 15min at RT in the dark in PBS con-
taining 2% FCS.
Cells were acquired on FACS Canto II, LSR II (BD Biosciences) and
data were analyzed using FlowJo software (Treestar Inc.). FACS Aria
(BD Biosciences) and Sony SH800 Cell (Sony Biotechnology Inc.,San
Jose, CA, US) were used for cell sorting.
2.11. TCR signaling and phospo-speciﬁc ﬂow cytometry
TCR activation was performed essentially as previously reported
[26]. In brief, APCs loaded with peptide at 10 μM ﬁnal concentration
(relevant or irrelevant) were used to activate the TCR. APCs and TCR-
NK-92 were mixed at 1:1 ratio. TCR activation was stopped at different
time points, 2, 5 and 15min, followed by PFA ﬁxation, permeabilization,
barcoding and antibody staining.
Antibody staining: p-CD3zeta, p-SLP76, p-Zap70 were all from BD
Biosciences, whereas p-ERK was from Cell Signaling Technologies (Lei-
den, The Nedherlands). Stained samples were collected on a LSRII ﬂow
cytometer (BD Biosciences). Data were analyzed using Cytobank Soft-
ware (http://www.Cytobank.org), and phosphorylation levels were cal-
culated relative to unstimulated T cells, using arcsinh transformed data.
2.12. In vitro killing assay
An Annexin V assaywas performed using an Incucyte S3 (Essen Bio-
Science, UK). Granta-519 were loaded or not with 10 μM of TGFβRII
frameshift peptide127–145 (KSLVRLSSCVPVALMSAMT), washed and re-
suspended in complete RPMI-1640 medium with 1:400 Annexin V red
(Essen BioScience, UK). Then cells were incubated in a 96-well plate
coatedwith Cell-Tak (Corning Inc., Corning, NY, US) for 15min at a den-
sity of 5000 cells per well. NK-92, CD3-NK-92 and TCR(Radium-1)-NK-92 cells were then added at a density of 20,000 cells per well. Two im-
ages per well were taken, each hour, using phase and red channel. Anal-
ysis was performed using Incucyte software. Killing was monitored by
following the density of red object/mm2 over time.
Non-radioactive EuropiumTDA (EuTDA) cytotoxicity assay based on
DELFIA technologywas performed. The EuTDAassay uses time-resolved
ﬂuorometry (TRF) and the measured ﬂuorescence signal correlates di-
rectly with the amount of lysed cells (PerkinElmer Inc., Boston, MA,
USA). TCR-NK-92 cells (Radium-1 and DMF-5) were stimulated for 2 h
with target cells (K562:HLA-A2) loaded with 10 μM of either the rele-
vant or irrelevant peptide and incubated at the indicated effector to tar-
get ratio (E:T), 25:1 and 50:1. Measurement of the ﬂuorescent signal
was performed on a VICTOR X4™ plate reader (PerkinElmer Inc).
2.13. Spheroids
Spheroids were obtained as in [27]: at day 8, 3 × 106 of either TCR
(Radium-1)-NK-92 or NK-92, or medium were added to the spheroid
cultures along with 10 μM of cognate peptide. Medium only cultures
were used as control. Size of the spheroids was monitored using an
Evosxl Core microscope and analyzed using Fiji and Wavemetrics.
2.14. In vivo studies
Two xenograft mouse models were implemented, respectively sub-
cutaneous and intraperitoneal. NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG)
micewere injectedwith 1 × 106 luciferase expressing HCT116. Eight in-
jections of 5 × 106 TCR(DMF-5)-NK-92 and TCR(Radium-1)-NK-92 cells
were performed in the tumor (i.t.) or at the same site at days 3, 6, 10, 12,
14, 17, 20 and 25 post tumor cell injections. Size of the tumor wasmon-
itored twice a week using a caliper and mice were sacriﬁced once the
tumor volume reached 2000 cm3.
2.15. Statistics
Unless stated otherwise, statistics were performed using
heteroscedastic two tails t-Student or Anova using R software. Kaplan-
Meier estimator was compared using log-rank test (Mantel-Haenszel
test). For all statistical test, *p b 0.05, **p b 0.01, ***p b 0.001.
3. Results
3.1. TCR-NK-92 express a functional TCR and are cytotoxic effector cells
The manufacture of TCR-NK-92 cells was performed in two steps
(Fig. 1a). First, a construct encoding the human CD3 complex (hCD3)
gene was designed as a polycistronic single chain in which CD3γ, δ, ε,
ζ coding sequences were linked by 2A ribosome skipping sequences
and its expression in primary human T cells was compared with a mu-
rine CD3 construct. CD3zeta was detected at the plasma membrane,
suggesting that the entire complex was formed (Fig. 1Sa,b). In contrast,
retrovirally transduced NK-92 cells with hCD3 (CD3-NK-92) did not
show surface expression of CD3 unless they were co-transduced with
TCR (Fig. 1b). Two therapeutic TCRs were selected, Radium-1 TCR spe-
ciﬁc for a TGFβRII frameshift mutation peptide (amino acids131–139,
pTGFβRII) [22] and the DMF-5 Melan-A speciﬁc TCR (amino
acids27–35, pMelan-A) [28]. The double-transduced CD3/TCR NK-92
cells, referred to as TCR-NK-92, demonstrated similar surface expres-
sion levels of CD3 (Fig. 1a,b and Fig. 1Sc).
To assess whether CD3/TCR gene editing of NK-92 could affect cellu-
lar functions we analyzed the gene expression of parental NK-92 and
monitored changes in gene expression in both TCR-NK-92 and CD3-
NK-92 (Fig. 1c). Surprisingly, pathway analysis of differentially
expressed genes using IPA® (Qiagen) revealed the interferon-
signaling pathway as the most activated (p-value: 6.9E-17; z-score:
3.9) in TCR-NK-92 cells; causedbyup-regulation of a signiﬁcant number
Fig. 1. Generation of a universal T cell-like lymphocyte for TCR expression. (a) Schematic overview of engineered TCR-NK-92 cells. NK-92 cells were retrovirally transduced with the
human CD3 polycistronic complex, CD3εγ, CD3εδ, and CD3ζζ dimers. CD3 engineered NK-92 cells were herein referred to as CD3-NK-92. The CD3 complex is localized in the
intracellular compartment. CD3-NK-92 were then super-infected with a TCRα-2A-TCRβ construct encoding a therapeutic TCR and referred to as TCR-NK-92. The CD3-TCR complex is
translocated on the cell surface. (b) Dot plots showing surface expression of CD3 in TCR-NK-92 (Radium-1 or DMF-5), CD3-NK-92 and parental NK-92 (representative of three
experiments). (c) Heatmap showing the relative expression of a relevant subset of genes belonging to the Interferon-signaling pathway for three replicates of TCR-NK-92, CD3-NK-92
and NK-92 in a pair-wise distance based on RNA sequencing.
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fection of NK-92 with hCD3 not followed by TCR (CD3-NK-92) did not
affect the expression of any of these genes in terms of mRNA transcrip-
tion when compared to parental NK-92 (data not shown and Fig. 1Sd).
Three interferon forms, alpha, beta and gamma, seemed to be
signiﬁcantly up-regulated. These ﬁndings indicate that TCR-NK-92
showed a novel gene expression pattern that resembles those of pri-
mary effector T and NK cells [29].
We next studied the protein quality of the transgenic TCR. To con-
ﬁrm correct folding of the TCR, we used a speciﬁc anti-TCR Vβ chain an-
tibody (anti-Vβ3) in TCR(Radium-1)-NK-92 cells or pMHC multimer
(Melan-A:HLA-A2 dextramer) in TCR(DMF-5)-NK-92 cells, respectively
(Fig. 2a,b). To investigate if the binding capacity of the transgenic TCRfor its cognate pMHC complex was conserved in TCR-NK-92 cells, 2-
color NTAmer technology was applied. This enables measurements of
monomeric TCR-pMHC dissociation rates (koff) and half-lives (t1/2)
directly at the surface of living cells [24]. This conﬁrmed that TCR
(DMF-5)-NK-92 cells had TCR-pMHC dissociation kinetic parameters
similar to Jurkat and primary T cells carrying DMF-5 (Fig. 2Sa,b). Know-
ing that the extracellular part of the TCR was functionally expressed in
TCR-NK-92, we next analyzed TCR signaling using phospho-ﬂow
cytometry [26]. Non-speciﬁc activation of TCR using anti-CD3 and
anti-CD28 antibodies induced strong phosphorylation of downstream
signaling molecules including CD3ζ, Zap70 and SLP76 in TCR(Radium-
1)-NK-92 cells, suggesting that the key players of the TCR signaling
cascade were present and active in TCR-NK-92 (Fig. 2Sc). In a more
Fig. 2. TCR-NK-92 in vitro validation. (a,b) Dot plots showing correct folding of two transgenic TCRs (Radium-1 TCR and DMF-5 TCR). Surface expression of aCD3 and aVb3 TCR antibodies
in NK-92, CD3-NK-92 and TCR(Radium-1)-NK-92 (left panel) and expression of aCD3 antibody and pMHC dextramer in NK-92, CD3-NK-92 and TCR(DMF-5)-NK-92 (right panel)
(representative of three experiments). (c,d) Phosphorylation of the key components of TCR signaling cascade, ERK, CD3zeta, SLP76 and ZAP70 overtime in TCR-NK-92 (either DMF-5
TCR or Radium-1 TCR) was detected by phospho-speciﬁc ﬂow cytometry upon stimulation with APCs loaded with either pMelan-A or pTGFβRII peptide. TCR-induced phosphorylation
was measured at 5, 15 min after addition of APCs to TCR-NK-92 cells, following a 30 s centrifugation to bring the cells together. (n= 2) Error bars represent SD. (e) Outcome of ViSNE
analysis on TCR-NK-92, NK-92 and T cells, either naïve or activated. (f) Bar graphs showing the level of IFNγ and TNFα produced by TCR(Radium-1)-NK-92 and CD3-NK-92 co-
cultured with K562:HLA-A2 that were loaded with either irrelevant peptide (pMelan-A) or cognate peptide (pTGFβRII) or used as negative control (no peptide). (n = 3). Error bars
represent SEM. (g) Dot plots showing frequency of activated TCR(Radium-1)-NK-92 cells. Detection of CD107a expression in TCR-NK-92 cells cultured in the presence of cognate
peptide (pTGFβRII). (n= 4). Error bars represent SEM.
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peptide-pulsed antigen-presenting cells (APCs), we observed pMHC-
induced phosphorylation in TCR-NK-92 cells only when the speciﬁc
peptide was presented (Fig. 2c,d and Fig. 2Sd).
Effector functions are also dependent on the signaling from other
regulatory receptors. To study the inﬂuence of the presence of CD3
and TCR in TCR-NK-92 cells, cells were phenotypically proﬁled and
compared with NK-92 and primary T cells from peripheral blood. We
observed that among the activating NK receptors, TCR-NK-92 cells
only showed modest levels of NKp30 (CD337), while NKp44 (CD336),
NKp46 (CD335) and NKG2D were not detectable (Fig. 3Sa). Of interest,
expression of these activating receptors was higher in parental NK-92.
Further, the co-stimulatory receptors CD226 and CD137 were notdetectable in TCR-NK-92, or in NK-92. This contrasted with the inhibi-
tory receptor CD96, which was always detected at high levels on both
TCR-NK-92 and NK-92 (Fig. 3Sa). To investigate how the activation is
differently impacting T cells, NK-92 and TCR-NK-92, we compiled a
panel of 35 lymphocyte-speciﬁc markers for mass cytometry. We ob-
served that TCR-NK-92 had an intermediate behavior between NK-92
and T cells; like T cells, TCR-NK-92 showed high level of CD28, but
like NK-92, they expressed fewer immune checkpoint proteins (PD1,
CTLA-4, TIGIT, TIM3 and LAG-3) in comparison with T-cells after a
short activation (Fig. 2e, and Fig. 3Sb). This last result holds
promise for TCR-NK-92 by combining the speciﬁcity and efﬁciency of
the T cell with an anticipated lower sensitivity to immune checkpoint
inhibition.
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and others previously showed that CAR provided antigen speciﬁcity to
NK cells while maintaining inherent NK-cell functions [30–32]. In
order to validate the functionality of the introduced TCR, we analyzed
the effector functions including cytokine release and degranulation of
TCR-NK-92 cells upon co-stimulation with target cells loaded with ei-
ther the cognate peptide or an irrelevant peptide. This demonstrated
that TCR-NK-92 produced IFNγ and TNFα in an antigen-speciﬁcmanner
(Fig. 2f). As expected, CD3-NK-92 cells did not show any antigen-
speciﬁc cytokine release. Degranulation was measured by CD107a de-
tection, which gives an indirect measurement of cytotoxicity [33]. The
majority of TCR-NK-92 cells stained positively for CD107a only in the
presence of the cognate antigen, demonstrating that degranulation
was antigen speciﬁc and thus TCR dependent (Fig. 2g). In general, secre-
tion of IFNγ andmobilization of CD107a correlate with the ability of the
effector cells to lyse target cells. Collectively, the results demonstrate
functional TCR can be expressed in manipulated NK cells.
3.2. TCR-NK-92 show T cell-related metabolic and phenotypic proﬁle
As metabolism and plasma membrane organization are critical fea-
tures in effector cell functions, we studied the metabolic activities of
TCR-NK-92 cells using SeaHorse technology. Oxygen Consumption
Rate (OCR) aswell as Extracellular Acidiﬁcation Rate (ECAR)weremea-
sured over time and modulated by metabolic drugs in order to extract
parameters of mitochondrial respiration and glycolysis in NK-92, CD3-
NK-92, TCR-NK-92, J6, J76 and J76-TCR cells. TCR-NK-92 and T cells
demonstrated a similar pattern in terms of basal respiration, as well as
ATP production and maximal respiration capacity in the presence of
anti-CD3 coated surface (Fig. 3a-c, Fig. 4Sa). This demonstrates the abil-
ity of the TCR-NK-92 to increase their oxidativemetabolism in response
to external activation stimuli, comparable to T cells. Furthermore, ECAR
and basal glycolysis measurements showed comparable glycolysis ac-
tivity for all cell lines independently of the presence of anti-CD3
(Fig. 3d and Fig. 4Sb-d).
Spreading over a surface is key to the T cell's physiological role of
recognizing rare and low abundance antigenic ligands on the surface
of antigen presenting cells [34]. The extent of T-cell spreading, while
interactingwith physiological ligands, is correlated with signal strength
[35] and represents some of the earlier critical events involved in TCR
triggering. We hypothesized that the introduction of CD3 and TCR into
NK-92 cells could create a T cell-like surface area where TCR-NK-92
cells adopt a similar behavior to what has been observed in T cells
upon APC contact [25]. To assess our hypothesis, we studied spreading
area, actin organization and CD3 clustering in TCR-NK-92 with Reﬂec-
tion Interference Contrast Microscopy (RICM) and Total Interference
Reﬂection Fluorescence (TIRF). Synthetic surfaces coated with anti-
CD3 or anti-HLA class I were used tomimic the surface of the APC carry-
ing agonist or antagonist peptides. TCR-NK-92 exhibited large spreading
adhesion after 15 min of contact on anti-CD3 than on anti-HLA class I
(Fig. 3e,f and Fig. 5Sa,b), comparable to primary T cells. This conﬁrmed
the ability of the TCR-NK-92 to maximize the surface of adhesion
upon activation mediated by the TCR in order to stabilize and sustain
the activation signal. Unlike TCR-NK-92 and T cells, NK-92 and CD3-
NK-92 cells did not respond to aCD3 coated surfaces, corresponding
with their lack of surface CD3 expression (Fig. 3e,h). Actin reorganiza-
tion is a key event in the process of T cell and APC encounter [36], per-
mitting clustering of TCR and its coalescence to form the immune
synapse. In this respect the ring formation, typical for the pre-
establishment of the immune synapse, was seen in TCR-NK-92 upon
anti-CD3 activation in a manner comparable to T cells (Fig. 3e,g and
Fig. 5Sc). Finally, using anti-CD3 staining, wewere able tomeasure sim-
ilar levels of membrane CD3 in both TCR-NK-92 and T cells (Fig. 3e,h).
Immune synapse (IS) formation is often designated a key event in
the complete and durable activation of the T-cell. It is composed of a po-
larized interface between the T-cell and the APC recognizable by thesegregation of various receptors in concentric ring33s. TCR molecules
are found in the center of the supramolecular activation cluster
(cSMAC) surrounded by a ring of integrins andﬁlamentous actin. Its for-
mation can be triggered by using a full-length anti-TCR antibody that
will cross-link several TCR molecules leading to the formation of TCR
microclusters that will coalesce into large clusters in IS-type fashion
[37]. We pre-incubated NK-92, TCR-NK-92 and T cells with an antibody
against the Vβ3 TCR chain prior to their incubation on aCD3 coated syn-
thetic surface. As shown (Fig. 3i) only TCR-NK-92 and T-cells were able
to form TCRmacroclusters in the center of the cell-surface contact zone.
The cSMAC zonewas surrounded by a ring of actin exhibiting the typical
IS structure. Moreover, TCR-NK-92 exhibited similar TCR density
(Fig. 3j) with a similar ability to cluster it (Fig. 3k). Taken together,
these results demonstrated that TCR-NK-92 cells are indeed like T cells
in terms of basic spreading morphodynamics.
3.3. TCR-NK-92 are therapeutic effector cells
We assessed the killing capacity of TCR-NK-92 by direct measure-
ment of their cytolytic capacity. HLA-A2 expressing K562 cells, which
are resistant to NK killing when compared to the original cell line,
were used as targets loaded with irrelevant or relevant peptide to
quantify TCR-NK-92 killing in a Europium assay (Fig. 4a, red). TCR(Ra-
dium-1)-NK-92 efﬁciently lysed K562:HLA-A2 in a peptide-dependent
manner, and as expected, no speciﬁc killing was observed when
irrelevant peptide was used. Similar observations were done with TCR
(DMF-5)-NK-92 (Fig. 4a, blue). Furthermore, long term anti-tumor ac-
tivity of TCR-NK-92 was conﬁrmed in vitro by Annexin V assay.
TCR(Radium-1)-NK-92 were tested against Granta-519 which is resis-
tant to NK-92 killing [30] loadedwith pTGFβRII (Fig. 4b, Supplementary
movie). Speciﬁc killing of Granta-519 was signiﬁcantly enhanced for
TCR(Radium-1)-NK-92 cells in comparison with NK-92 or CD3-NK-92
cells, demonstrating the advantage of guiding NK-92 cells with a TCR
to eliminate cancers. Collectively, the in vitro data showed that TCR-
NK-92 cells acquired T cell-like properties in terms of antigen discrimi-
nation, cytokine secretion, degranulation and cytotoxicity.
As a ﬁrst indication of in vivo anti-tumor efﬁcacy, we challenged
TCR-NK-92 with spheroids of colorectal cancer cells HCT116 which are
HLA-A2+ and express the TGFβRII frameshift mutant endogenously
[38]. The goal was to reproduce in vitro the tumor morphology and its
microenvironment in order to evaluate TCR-NK-92 potency against a
structured target [27]. HCT116 spheroids were left to grow for 8 days
and co-cultured or not with TCR(Radium-1)-NK-92 or TCR(DMF-5)-
NK-92. Only TCR(Radium-1)-NK-92 were able to control the growth
of HCT116 spheroids (Fig. 4c,d).
We then evaluated the in vivo anti-tumor activity of TCR-NK-92 cells
in NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG)mice subcutaneously injected
with luciferase-expressing HCT116 colorectal cancer cells (Fig. 4e). The
tumor load was signiﬁcantly lower in mice that received TCR(Radium-
1)-NK-92 treatment as compared to control mice receiving TCR(DMF-
5)-NK-92 (Fig. 4f). Mice receiving the therapeutic TCR-NK-92 cells
also had signiﬁcantly enhanced survival compared with control mice
(Fig. 4g). Taken together, the results from the pre-clinical in vivo
study showed potential therapeutic efﬁcacy of TCR-NK-92.
4. Discussion
In this report we showed that an NK cell line, NK-92, can be turned
into a T-cell like effector cell by introducing the genes encoding the
CD3 subunits. In agreement with our previous results [30] a full-
length TCR alone cannot be expressed at the plasma membrane of NK-
92 cells, and it is only by modifying the transmembrane region that
the TCR can be exported. In addition to being correctly transported to
the plasma membrane, we herein demonstrated that the protein was
correctly folded and functional. The time of TCR residency at the
membrane was sufﬁcient for its detection and binding its substrate.
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Fig. 4. TCR-NK-92 mimic T cells in their lytic effector functions both in vitro and in vivo. (a)-Antigen-speciﬁc lytic function of TCR-NK-92 cells (Radium-1 and DMF-5) measured by
europium release assay. Bar graph showing % of target cells (K562:HLA-A2), either loaded or not with the cognate peptide, that were killed at 50:1 or 25:1 E:T ratio. (n = 3). Error
bars represent SD. (b) Kinetic of tumor cell killing. TCR(Radium-1)-NK-92, NK-92 and CD3-NK-92 were co-cultured with Granta-519 cells either expressing or not the cognate peptide
(pep). The killing is expressed as red object density by Annexin V assay. (n = 32). Error bars represent SD. (c) Representative micrographs of HCT116 spheroids treated with TCR
(Radium-1)-NK-92, TCR(DMF-5)-NK-92 or medium. Scale bar 200 μm. (d) Evolution of the average spheroids size upon treatment with TCR(Radium-1)-NK-92, TCR(DMF-5)-NK-92 or
medium. (n= 28). Error bars represent SD. (e) Design of in vivo experiment using HCT116 xenograft mouse model. 10 mice per condition. (f) Evolution of tumor volume over time in
treated (TCR(Radium-1)-NK-92) and untreated (TCR(DMF-5)-NK-92) mice. Error bars represent SD. (g) Corresponding Kaplan-Meier estimator.
Fig. 3. TCR-NK-92 acquire T-cell like behaviors in terms ofmetabolic functions, morphodynamics and immune synapse. (a-c)Mitochondrial respiration. Oxygen Consumption Rate (OCR)
of NK-92, CD3-NK-92, TCR(Radium-1)-NK-92, J6, J76 and J Radium-1 over time, in the presence or not of anti-CD3 (aCD3). Mitochondrial respiration function (expressed as OCR rate)was
measured, ﬁrst at baseline and, then, probed by the serial addition of oligomycin, FCCP and antimycin-A/rotenone (anti-A+ rot). (a) Basal respiration, (b) ATP production and (c)maximal
respiration capacity measured in NK-92, CD3-NK-92, TCR(Radium-1)-NK-92, J6, J76 and J Radium-1, either CD3 treated or untreated. (n=21). Error bars represent SD. (d) ExtraCellular
Acidiﬁcation Rate (ECAR) of NK-92, CD3-NK-92, TCR(Radium-1)-NK-92, J6, J76 and J Radium-1, either CD3 treated or untreated, before and after addition of oligomycin is shown.
Comparison of basal glycolytic activity between effector cells, either CD3 treated or untreated. (n = 21). Error bars represent SD. (e) Representative Reﬂection Interference Contrast
(RIC) and TIRF micrographs of lymphocyte adhesion (RICM), actin and CD3 organization obtained after 20 min of spreading on glass slides coated with anti-HLA class I or -CD3. Scale
bar 5 μm. (f) Box plot of contact area as determined from segmentation of RICM images. (g) Box plot of actin centrality. (h) Box plot of CD3 intensity at the cell-surface contact zone.
For all box plots, n ≥ 50 cells per condition. (i) Confocal images of NK-92, TCR-NK-92 and T-cell previously activated and marked with anti Vβ3 (green) and phalloidin (red). Scale bar
4 μm. (j) Box plot of the anti Vβ3 signal intensity (n = 25). Error bars represent SD. (k) Box plot of the centralization of TCR molecules (cSMAC-number) (n = 25). Error bars
represent SD.
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molecular interface of the TCR and its binding strength were compara-
ble in the NK-92 and in the T-cell backgrounds. Although the TCR at
the surface of TCR-NK-92 cells could recognize speciﬁc targets
(pMHC), it was not obvious whether it would be able to transduce the
pMHC-stimulation signal. Remarkably, when the TCR signalingmachin-
ery was transplanted to Hek cells, a battery of signaling proteins needed
to be added to mimic the TCR in a T-cell environment [39]. Whereas in
the context of NK-92, the TCR stimulation could trigger effector func-
tions similar to those observed in T cells only by the addition of the
CD3 complex. In this line, the gene expression proﬁling of TCR-NK-92
emphasized the potentiality of these cells to acquire a “ﬁt” phenotype
for becoming a potent T-cell like killer. Thiswas observedwithout exog-
enous stimulation of the TCR, suggesting that the tonic signaling was
sufﬁcient to shape the genetic proﬁle of anNK cell to a T-cell like proﬁle.
Therefore it is reasonable to assume that this new acquired gene proﬁle
might translate into a T-cell-like phenotype. We ﬁnally demonstrated
that this “neo-T cell line” was functional in a pre-clinical setting, and
that the presence of a TCR boosted target recognition potentially to
the whole proteome.
The costs and the technical challenges of personalized redirected T-
cell production represent a serious brake for the broad clinical applica-
tion of cellular therapy against cancer. In addition, patients who have
been through several rounds of treatments before TCR-based therapy
might not qualify for treatment with autologous material due to the
poor quality of their immune cells. To increase the feasibility of person-
alized cancer treatment andmake it applicable also to patients with the
most advanced disease, distinct strategies have been investigated to
generate a universal antitumor T cell. Such a universal T cell will facili-
tate and shorten the clinical grade manufacturing in terms of ex vivo
T-cell genetic manipulation, storage and validation. Generation of a uni-
versal T cell from a third party has already been exploited and seems ap-
pealing [40]. However, strategies to knock-down the endogenous TCR
and the HLA should be included to avoid unpredictable off-target toxic-
ities due to the endogenous TCR and rejection of the infused allogeneic T
cells because of MHC mismatch. Using allogeneic T cells with deﬁned
speciﬁcity for virus [41] and,more recently, strategies to genetically dis-
rupt endogenous TCR expression have been proposed to improveFig. 5. Technical advantages of TCR-NK-92 based immcontrol of the endogenous TCR activity [42–45]. Despite the encourag-
ing results obtained by these strategies it is still not possible to
completely exclude the risks of off-target toxicity and GVHD. Tech-
niques to disrupt the endogenous TCR gene are still not optimal suggest-
ing that purging unmodiﬁed T cells would be needed which would
make the manufacturing process even more laborious. Lymphoid pro-
genitors [46,47] and pluripotent stem cells [48,49] have also been
exploited as a source of universal T cells for CAR and/or TCR therapy be-
cause they do not initiate any GVH reactions. However, the genomic in-
stability and high genetic variations observed in iPSCs have raised
serious concerns about their safety for clinical applications [50].
In contrast to T cells, TCR-NK-92 do not express any endogenous
TCR. Moreover, recent clinical trials where NK-92 were infused have
shown that despite their allogeneic origin the NK-92 did not cause se-
vere toxicities andwere poorly immunogenic and therefore not rejected
by the host [11,12]. The main advantages of using TCR-NK-92 if com-
pared to other sources of universal T cells is that they are an homoge-
nous, well deﬁned cell population; furthermore they are indeﬁnitely
expandable and easy to genetically manipulate. It is also worth noting
that a strain of NK-92 independent of hIL-2 has been developed and is
currently being tested in patients (ClinicalTrials.gov Identiﬁer:
NCT03027128), this could easily be repeated in TCR-NK-92 and would
reduce the manufacturing costs even further. Therefore, stocks of TCR-
NK-92 already reprogrammed to express different therapeutic TCRs
could be frozen and maintained in a therapeutic biobank. TCR therapy
would be readily available for patients with tumor antigens and HLA
matching the TCRs existing in the TCR-NK-92 format (Fig. 5). Finally,
the cell line used in the current study originates from non-GMP compli-
ant stocks obtained through ATCC and may be different the GMP com-
pliant derivatives currently under clinical investigation in FDA
approved trials. We however have data showing that other NK cell
lines can be redirected with TCR in the same way as TCR-NK-92
(Mensali and Wälchli, unpublished data). It is however obvious that if
the FDA strain could be used, most of the presented experiments
might need to be repeated, especially the gene expression analysis
and the killing ability upon cell culture under GMP conditions. The over-
all encouraging data presented in the study offered the proof-of-
principle for the use of a Universal Killer Cells engineered to expressunotherapy over T-cell based immunotherapy.
116 N. Mensali et al. / EBioMedicine 40 (2019) 106–117therapeutic TCRs for adoptive cell-based cancer therapy. Further studies
are needed to conﬁrm the potentiality of TCR-NK-92 cells and could
pave the way for these cells as an “off-the shelf therapeutic live drug”.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.01.031.
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